Share on LinkedInShare on LinkedIn

ARTICLE · 21 OCTOBER 2005

Proposed Canadian Amendments Will Affect Innovative Drug Companies

Torys
Torys
Contributor
Torys

Torys

Torys LLP is an international business law firm that works with clients who expect the best advice...

View firm profile
Explore more from Torys

The government of Canada recently published proposed amendments to the Patented Medicines (Notice of Compliance) Regulations and to the Food and Drug Regulations that will affect innovative drug companies.

CanadaIntellectual Property

By Conor McCourt

This article first appeared in the May/June 2005 issue of Update. Reprinted with the permission of the Food and Drug Law Institute (FDLI) © 2005.

The government of Canada recently published proposed amendments1 to the Patented Medicines (Notice of Compliance) Regulations2 and to the Food and Drug Regulations3 that will affect innovative drug companies. These regulations create the regulatory framework that, together with patent enforcement proceedings under Canada’s Patent Act,4 governs the protection of pharmaceutical patents. The proposed amendments seek to alter this regulatory framework as follows:

  • restricting the application of the Patented Medicine (Notice of Compliance) Regulations, most notably by limiting an innovator’s ability to list and enforce patents on the patent register maintained by the Minister of Health; and

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from